EGFR and non-small cell lung carcinoma: Similarly, third-generation inhibitors (such as osimertinib and rociletinib) have shown limited efficacy in pre-clinical and clinical studies in NSCLC patients with EGFR Ex20ins who have failed standard platinum chemotherapy [52,70,71].